3271F Low risk prostate cancer
Also known as: low-risk prostate cancer staging, favorable-risk prostate cancer, T1-T2 Gleason 6 PSA <10
Performance measure for prostate cancer classified as low-risk disease. Quality metric documenting risk stratification for treatment planning and monitoring decisions.
In Plain Language
early stage slow-growing prostate cancer
Clinical Context
Quality measure for prostate cancer risk assessment, used to guide treatment decisions between active surveillance, radiation, or surgery based on disease characteristics.
RVU Information
CPT 3271F does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Documentation should include the clinical indication, service details, and any applicable performance metrics. Coverage may vary by payer — verify acceptance before billing.
Specialties
Frequently Asked Questions
What is CPT code 3271F?
CPT 3271F (Low risk prostate cancer) is a Other code. Performance measure for prostate cancer classified as low-risk disease. Quality metric documenting risk stratification for treatment planning and monitoring decisions.
Who uses CPT code 3271F?
CPT 3271F is used by Urology, Oncology, Quality Reporting. Quality measure for prostate cancer risk assessment, used to guide treatment decisions between active surveillance, radiation, or surgery based on disease characteristics.
When is CPT 3271F used?
Quality measure for prostate cancer risk assessment, used to guide treatment decisions between active surveillance, radiation, or surgery based on disease characteristics.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.